Internal Medicine, Gastroenterology · Charleston, SC
NPI
1821094301
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
1962 Charlie Hall Blvd
Charleston, SC, 29414
Phone (843) 722-8000
Groups this clinician bills Medicare through
Medicare paid, 2024
$276K
2,348 services
Medicare patients, 2024
1,145
Average age 74
Drug cost, 2024
$979K
3,371 prescriptions
Company payments, 2025
$135
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Theodore G Gourdin was code 99215 (office e&m - established), 504 times for 382 patients. In total Theodore G Gourdin billed 2,348 services in 40 codes, and Medicare paid $276K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-05-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 504 | 382 | $125.56 | $63K |
| 43239 Upper GI Endoscopy | Facility | 373 | 368 | $69.23 | $26K |
| 45385 Colonoscopy - Lesion Removal | Facility | 245 | 245 | $193.81 | $47K |
| 99204 Office E&M - New | Office | 240 | 240 | $112.67 | $27K |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 156 | 156 | $168.47 | $26K |
| 45378 Lower GI Endoscopy - Other | Facility | 105 | 105 | $129.64 | $14K |
| 43450 Digestive/Gastrointestinal | Facility | 104 | 103 | $28.92 | $3,008 |
| 45380 Lower GI Endoscopy - Other | Facility | 92 | 92 | $122.55 | $11K |
| 74177 CT/CTA - Abdomen and Pelvis | Office | 80 | 79 | $149.42 | $12K |
| 99232 Hospital E&M - Subsequent | Facility | 71 | 24 | $58.80 | $4,175 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 70 | 70 | $163.92 | $11K |
| 82274 Immunoassay | Office | 49 | 49 | $15.60 | $764 |
| 76705 Ultrasound - Abdomen and Pelvis | Office | 38 | 36 | $36.98 | $1,405 |
| 76700 Ultrasound - Abdomen and Pelvis | Office | 37 | 35 | $48.44 | $1,792 |
| 99214 Office E&M - Established | Office | 36 | 34 | $71.15 | $2,561 |
By year: 2022 $330K for 2,867 services; 2023 $291K for 2,467 services; 2024 $276K for 2,348 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82274 Immunoassay | 49 | 49 | $15.60 | $764 |
Medicare prescription drug claims, 2024
In 2024, the drug Theodore G Gourdin prescribed most often to Medicare patients was Pantoprazole Sodium, with 1,038 prescriptions and refills. In total Theodore G Gourdin wrote 3,371 Medicare prescriptions that cost $979K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 1,038 | 2,287 | 343 | $15K |
| Dicyclomine Hcl Generic | 367 | 548 | 184 | $10K |
| Famotidine Generic | 167 | 419 | 55 | $3,790 |
| Esomeprazole Magnesium Generic | 163 | 324 | 43 | $8,170 |
| Omeprazole Generic | 149 | 393 | 54 | $2,293 |
| Metronidazole Generic | 144 | 144 | 126 | $946 |
| Colestipol Hcl Generic | 137 | 177 | 45 | $9,789 |
| Metoclopramide Hcl Generic | 102 | 145 | 37 | $359 |
| Budesonide Dr Budesonide | 89 | 103 | 17 | $21K |
| Linzess Linaclotide | 85 | 196 | 41 | $103K |
| Sucralfate Generic | 80 | 102 | 26 | $9,382 |
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 48 | 48 | 45 | $1,020 |
| Lansoprazole Generic | 46 | 131 | 14 | $1,799 |
| Colesevelam Hcl Generic | 46 | 82 | 11 | $6,743 |
| Amitriptyline Hcl Generic | 46 | 80 | 18 | $413 |
Brand drugs: - claims; generic drugs: 2,986 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Theodore G Gourdin $135 ($135 in general payments such as food, travel and fees) from 6 companies. The largest payer was Sandoz Inc. with $32.37.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.